<div id="readability-page-1"><article>Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (&#34;InMed&#34; or the &#34;Company&#34;), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. (&#34;Armistice&#34;) in respect of certain outstanding preferred investment options held by Armistice.As previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023 issued to Armistice (the &#34;Armistice Preferred Investment Options&#34;), the Company provided Armistice with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the Company at an exercise price per common share of $16.60, subject to adjustment (the &#34;Armistice Exercise Price&#34;). The Company has entered into an amending agreement with Armistice in respect of the Armistice Preferred Investment Options to amend the Armistice Exercise Price from $16.60 to $0.80. The Armistice Preferred Investment Options were offered in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Armistice Preferred Investment Options will be exercised.For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.About InMedInMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information:This news release contains &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Armistice Preferred Investment Options prior to their expiration.With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.<img id="corporateNewsLogo" src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="187" height="94" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg"/>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297903<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375"/></article></div>

ARKG

InMed Pharmaceuticals Inc. has amended its agreement with Armistice Capital Master Fund Ltd. regarding preferred investment options. The exercise price for purchasing common shares has been reduced from $16.60 to $0.80. The options were part of a private placement under the Securities Act. There is no guarantee that the options will be exercised.

InMed Pharmaceuticals Amends Preferred Investment Options | INM Stock News